People with multiple sclerosis (MS) exhibit similar incidence, risk factors and outcomes for COVID-19 to the general population, with a potentially higher risk of disease and lower rates of seroconversion amongst those receiving long-term anti-CD20 therapy.
Why this matters
The region of Catalonia in Spain has experienced a significant burden of COVID-19. In general, people with MS prescribed disease-modifying therapies (DMTs) are at increased risk of infection and infection-related mortality than healthy people; however, it is also possible that immunosuppressive therapy could be beneficial in COVID-19. Overall, it remains unclear how diagnosis with MS and prescribing of specific DMTs may affect risk and outcome of COVID-19.